-+ 0.00%
-+ 0.00%
-+ 0.00%

Genentech initiates Phase II trial of RG6434 in early symptomatic Alzheimer's disease

PUBT·11/10/2026 06:01:39
Listen to the news
Genentech initiates Phase II trial of RG6434 in early symptomatic Alzheimer's disease
  • Genentech and Roche are initiating Phase II TARBELA-AD to evaluate oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease, targeting neuroinflammation.
  • Trial designs and new research will be presented at the CTAD Congress in Boston, November 16-19, 2026.
  • Updated Phase Ib/IIa trontinemab data show rapid amyloid removal and changes in key biomarkers.
  • Phase III PrevenTRON has begun enrolling cognitively unimpaired participants with Alzheimer's biomarkers at high risk of clinical decline to evaluate trontinemab.
  • Diagnostic presentations will examine clinical performance and economic implications of Elecsys pTau217 and pTau181 blood tests across care settings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.